Patents by Inventor Dario G. Gomez

Dario G. Gomez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20230062049
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 9, 2021
    Publication date: March 2, 2023
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20200330428
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 25, 2019
    Publication date: October 22, 2020
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20180344692
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20180071260
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 15, 2018
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Methods of treating ? adrenergic mediated conditions
    Patent number: 9849113
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20170172982
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Methods of treating ? adrenergic mediated conditions
    Patent number: 9623006
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: April 18, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Coumarin compounds as receptor modulators with therapeutic utility
    Patent number: 9572792
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: February 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
    Publication number: 20150265573
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: June 3, 2015
    Publication date: September 24, 2015
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20150224080
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: April 21, 2015
    Publication date: August 13, 2015
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Coumarin compounds as receptor modulators with therapeutic utility
    Patent number: 9073888
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: July 7, 2015
    Assignee: Allergan, Inc.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • Methods of treating alpha adrenergic mediated conditions
    Patent number: 9034910
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 19, 2015
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY
    Publication number: 20120328661
    Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
    Type: Application
    Filed: October 20, 2010
    Publication date: December 27, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Todd M. Heidelbaugh, John R. Cappiello, Phong X. Nguyen, Dario G. Gomez
  • Selective alpha 2B/2C agonists
    Patent number: 8329918
    Abstract: Described herein are compounds useful as agonists of alpha 2B/2C receptors. Pharmaceutical compositions including the presently described compounds and methods of treatment of diseases and conditions with the presently described compounds also are disclosed.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: December 11, 2012
    Assignee: Allergan Inc.
    Inventors: Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Wenkui K. Fang, Santosh C. Sinha, Michael E. Garst, Daniel W. Gil
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20120165380
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: October 17, 2011
    Publication date: June 28, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS
    Publication number: 20120035235
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 9, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha, Daniel W. Gil, John E. Donello
  • Methods of treating alpha adrenergic mediated conditions
    Patent number: 8071636
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: December 6, 2011
    Assignee: Allergan, Inc.
    Inventors: Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha, Daniel W. Gil, John E. Donello
  • 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazole-2-ones and related compounds
    Patent number: 8071635
    Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
    Type: Grant
    Filed: February 16, 2008
    Date of Patent: December 6, 2011
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Todd Heidelbaugh, Daniel Gil, Michael Garst, Larry A. Wheeler, Phong X. Nguyen, Dario G. Gomez
  • Methods of treating alpha adrenergic mediated conditions
    Patent number: 8063231
    Abstract: Described herein are novel N-(2 and/or 3-substituted benzyl)-4,5-dihydro-1H-imidazol-2-amine derivatives processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals modulators of subtype ?2B and/or ?2C adrenergic receptors.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds
    Patent number: 8063087
    Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: November 22, 2011
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Todd Heidelbaugh, Daniel Gill, Michael Garst, Larry A. Wheeler, Phong X. Nguyen, Dario G. Gomez